ASCLS eNewsBytes

• Study Links COVID-19 and Bacterial Infection to Alzheimer'S Disease July 15, 2025
  Chlamydia pneumoniae and SARS-CoV-2 infections may contribute to Alzheimer's disease by increasing cytokine levels in the brain, leading to inflammation and the accumulation of harmful proteins.
• FDA Grants Orphan Drug Status to STEAP1-Targeting ADC for Gastric Cancer July 15, 2025
  FDA grants orphan drug designation to Adcentrx Therapeutics' ADRX-0405 for gastric cancer treatment, providing regulatory and financial incentives for rare disease therapies.
• FDA Expands Approval of MRI-Guided Ultrasound Treatment for Patients With Parkinson's Disease July 15, 2025
  FDA approves Exablate Neuro, MRI-guided ultrasound treatment for advanced Parkinson's disease patients, providing targeted pallidothalamic tract treatment and a viable alternative for dyskinesia, bradykinesia and rigidity.
• Olanzapine/Triplet Cuts Chemo-Induced Nausea, Vomiting in Breast Cancer July 15, 2025
  A phase 3 trial found that adding olanzapine to triplet antiemetic therapy improved antiemetic efficacy in breast cancer patients compared to placebo, with a 22.7% difference in complete response rates.
• FDA Grants Full Approval to mRNA-1273 COVID-19 Vaccine in Children at Increased Risk July 15, 2025
  The FDA has approved the supplemental biologics application for mRNA-1273, a COVID-19 vaccine, for children aged six to11 years at high risk, ensuring protection against severe disease and hospitalization.